Significant Ownership of Lynx1 Capital Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Lynx1 Capital Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Weston Nichols - By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
- Manager location
- Dorado
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Lynx1 Capital Management LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Lynx1 Capital Management LP
Significant Ownership of Lynx1 Capital Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PASG | Passage BIO, Inc. | Common Stock, par value $0.0001 per share | 21% | $262,766 | +$19,521 | 673,759 | +8% | Lynx1 Capital Management LP | 25 Jun 2026 |
| GHRS | GH Research PLC | Ordinary Shares, nominal value $0.025 per share | 19% | $356,649,814 | +$67,225,000 | 13,263,288 | +23% | Lynx1 Capital Management LP | 30 Jun 2026 |
| NEUP | Neuphoria Therapeutics Inc. | Common Stock, par value $0.00001 per share | 16% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| CGEM | Cullinan Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 14% | $50,697,778 | +$24,599,905 | 8,549,084 | +94% | Lynx1 Capital Management LP | 08 Oct 2025 |
| TCRX | TScan Therapeutics, Inc. | Voting Common Stock, par value $0.0001 per share | 13% | $25,854,126 | +$15,953,869 | 20,519,148 | +161% | Lynx1 Capital Management LP | 30 Jun 2026 |
| KRRO | Korro Bio, Inc. | Common Stock, par value $0.001 per share | 11% | $18,351,871 | +$9,599,630 | 1,538,296 | +110% | Lynx1 Capital Management LP | 31 Mar 2026 |
| CCCC | C4 Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 10% | $66,167,634 | +$35,716,644 | 15,423,691 | +117% | Lynx1 Capital Management LP | 30 Jun 2026 |
| STOK | Stoke Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 6.5% | $126,725,118 | -$22,758,941 | 4,038,404 | -15% | Lynx1 Capital Management LP | 30 Jun 2026 |
| DTIL | PRECISION BIOSCIENCES INC | Common Stock, par value $0.000005 per share | 5.4% | $10,951,062 | +$3,123,997 | 1,390,611 | +40% | Lynx1 Capital Management LP | 13 Jul 2026 |
| IBIO | iBio, Inc. | Common Stock, $0.001 par value per share | 5.4% | $4,070,173 | +$4,070,173 | 2,807,016 | Lynx1 Capital Management LP | 30 Jun 2026 | |
| AGIO | AGIOS PHARMACEUTICALS, INC. | Common Stock, par value $0.001 per share | 5.1% | $105,819,749 | 3,013,949 | Lynx1 Capital Management LP | 29 Apr 2026 | ||
| ALLO | Allogene Therapeutics, Inc. | Common Stock, par value $0.001 per share | 0% | $0 | -$26,534,324 | 0 | -100% | Lynx1 Capital Management LP | 31 Dec 2025 |
Schedules 13D/G Reported by Lynx1 Capital Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.